



## PRESCRIPTION FORM

**Access Pathways® Program Support:**

**Monday-Friday: 8am-8pm EST: Phone: 1-866-923-1954 Fax prescription forms: 1-877-788-4948**

**Weekends and After Hours: Phone: 1-866-923-1954 Fax prescription forms: 1-877-827-0395**

### HEALTHCARE PROVIDER INSTRUCTIONS:

1. Have your patient (or patient representative) read the "AUTHORIZATION TO SHARE HEALTH INFORMATION WITH VIGADRONE ACCESS PATHWAYS PROGRAM." Request that the patient (or patient representative) complete the section in the VIGADRONE PRESCRIPTION FORM under "PATIENT INFORMATION". Then have the patient (or patient representative) sign the form in this section.
2. Complete the rest of the PRESCRIPTION FORM under "HEALTHCARE PROVIDER INFORMATION" and attach a copy of both sides of the patient's pharmacy benefit card(s), if available.
3. Fax the completed PRESCRIPTION FORM along with copies of the patient's pharmacy benefit card(s) (both front and back) to the appropriate fax number above, or mail to 24 Summit Park Drive, Suite 101, Pittsburgh, PA 15275.
4. The Access Pathways® Program will process the PRESCRIPTION FORM and contact your patient (or the patient representative).
5. Prior authorization assistance will only be provided for the indicated disease states. Medicare, Medicaid and other federal or state program health care patients may be ineligible for certain other aspects of the VIGADRONE ACCESS PATHWAYS® PROGRAM.

### PATIENT INSTRUCTIONS:

Your healthcare provider will submit the completed VIGADRONE PRESCRIPTION FORM to the Access Pathways Program; we will process your request. **If you have questions, please contact us at 1-866-923-1954.**

### AUTHORIZATION TO SHARE HEALTH INFORMATION WITH VIGADRONE ACCESS PATHWAYS PROGRAM:

Please read the following. If you agree, sign and date the corresponding section of the VIGADRONE PRESCRIPTION FORM.

#### **AUTHORIZATION TO SHARE HEALTH INFORMATION WITH VIGADRONE ACCESS PATHWAYS PROGRAM**

By signing this authorization, I authorize my healthcare provider, my health and prescription insurance company, and my pharmacy providers ("Healthcare Entities") to disclose to Upsher-Smith Laboratories, LLC ("Upsher-Smith"), or companies working with Upsher-Smith (collectively, "Upsher-Smith Providers") or use, health information related to my (or the patient I am representing) medical condition, treatment, and insurance coverage ("Information") for the purposes of providing me with support services such as online support, financial assistance services, benefits verification, prior authorization, compliance and persistency, and education related to VIGADRONE and conduct data analytics and other business activities related to such services. Once my Information has been disclosed to Upsher-Smith Providers, I understand that federal privacy laws may no longer protect the information. I understand that Upsher-Smith Providers and Healthcare Entities may receive payment from Upsher-Smith in exchange for using or disclosing my Information. I understand that I may refuse to sign this Authorization. I further understand that my treatment is not conditioned upon my agreement to sign this Authorization; but if I do not sign it or later cancel it, I will not be able to receive Program services. I may cancel this Authorization at any time by mailing a letter to: 24 Summit Park Drive Suite 101, Pittsburgh, PA 15275. Canceling this authorization will not affect previous disclosures pursuant to this authorization. This authorization expires in one (1) year, from the day I sign it as indicated by the date next to my signature unless I revoke it before. I understand I have a right to have a copy of this form. Please sign in the space in the PATIENT INFORMATION section on the following page to authorize your consent.

**Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss, on page 4. For more information, please see full Prescribing Information and Medication Guide or go to [VIGADRONE.com/PI](http://VIGADRONE.com/PI)**

**PATIENT INFORMATION**

Name (First, Middle, Last) \_\_\_\_\_ Date of Birth \_\_\_\_\_

Address \_\_\_\_\_ Gender: Male Female

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_ Phone \_\_\_\_\_

Does the patient have any known allergies? (required) None Known \_\_\_\_\_

Please list the names of other medications the patient is currently taking.

None Medications \_\_\_\_\_

**Prescription Drug Coverage & Insurance Information**

Please check the following that best describes the patient's coverage:

Primary Insurance Type: Commercial Medicare Part D Medicaid No Insurance Other \_\_\_\_\_

Plan Name \_\_\_\_\_ Member # \_\_\_\_\_ Group # \_\_\_\_\_

Policy Holder Name \_\_\_\_\_ RxBin # \_\_\_\_\_ RxPCN # \_\_\_\_\_

Relationship to Policy Holder \_\_\_\_\_ Does patient have secondary insurance? Yes No

**NOTE:** Medical insurance information cannot be used to determine prescription benefit.

**AUTHORIZATION TO SHARE HEALTH INFORMATION WITH VIGADRONE ACCESS PATHWAYS PROGRAM**

I have read and understand the Authorization to Share Health Information with VIGADRONE ACCESS PATHWAYS PROGRAM and agree to the terms.

Signature of Patient or Patient Representative \_\_\_\_\_ Date \_\_\_\_\_

If signed by patient representative, please print your name below and provide your relationship to the patient:

**HEALTHCARE PROVIDER INFORMATION**

**Prescriber Information**

Name (First, Middle, Last) \_\_\_\_\_ Office contact name \_\_\_\_\_

Address \_\_\_\_\_ Best time to contact \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_ Please include preferred method of contact:

NPI # \_\_\_\_\_ Phone \_\_\_\_\_

State License # \_\_\_\_\_ Fax \_\_\_\_\_

**HEALTHCARE PROVIDER: Please include the following documents:**

1. Patient's prescription for VIGADRONE (see next page) or **electronically prescribe to E-Scribe (NABP) 6001565.**

**For questions please call 1-866-500-4570.**

2. Copies of the patient's pharmacy benefits card(s) front and back, if available.

**Authorized Provider**

I authorize Upsher-Smith, on behalf of my patient, to forward to the pharmacy and/or insurer the above information required by the insurer for the purpose of conducting a benefit verification.

Prescriber Signature \_\_\_\_\_ Date \_\_\_\_\_

**Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss, on page 4.**

**For more information, please see full Prescribing Information and Medication Guide or go to VIGADRONE.com/PI**

**Please submit completed pages 2 & 3 and accompanying information by fax, or mail to 24 Summit Park Drive, Suite 101, Pittsburgh, PA 15275**

**STARTER PRESCRIPTION**

This starter prescription is available to patients who have been prescribed VIGADRONE for an indicated disease state. This prescription allows patients access to VIGADRONE while VIGADRONE benefits investigation is ongoing (a limited supply may be provided during this time). This prescription will be filled by PANTHERx<sup>®</sup> Specialty Pharmacy.

 Patient Name: \_\_\_\_\_ Weight (kg): \_\_\_\_\_ Height (in): \_\_\_\_\_ Date of measurements: \_\_\_\_\_  
(mo./day/year)

 Date of Birth \_\_\_\_\_ Serum creatinine (mg/dL): \_\_\_\_\_ Date of measurement: \_\_\_\_\_  
(mo./day/year)

Prescription: VIGADRONE 500-mg powder for oral solution      Quantity (up to 7 days): \_\_\_\_\_

Today's date (month/day/year): \_\_\_\_\_ Refills (up to 3): \_\_\_\_\_

SIG: \_\_\_\_\_

Primary ICD-10 Code: \_\_\_\_\_ Secondary ICD-10 Code: \_\_\_\_\_

**Ship to:**  
 Name \_\_\_\_\_ Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_ Phone \_\_\_\_\_

**PRESCRIBER SIGNATURE**  
 (Physician attests this is his/her legal signature. **NO STAMPS**)

**DATE**

**Notes:** The prescriber should comply with state-specific prescription requirements. Noncompliance could result in outreach to the prescriber. All Access Pathways terms and conditions apply.

**PRESCRIPTION**

This prescription will be filled by PANTHERx<sup>®</sup> Specialty Pharmacy. Up to a 12-month supply may be prescribed.

 Patient Name: \_\_\_\_\_ Weight (kg): \_\_\_\_\_ Height (in): \_\_\_\_\_ Date of measurements: \_\_\_\_\_  
(mo./day/year)

 Date of Birth \_\_\_\_\_ Serum creatinine (mg/dL): \_\_\_\_\_ Date of measurement: \_\_\_\_\_  
(mo./day/year)

Prescription: VIGADRONE 500-mg powder for oral solution      Quantity: \_\_\_\_\_

Today's date (month/day/year): \_\_\_\_\_ Refill Quantity: \_\_\_\_\_

SIG: \_\_\_\_\_

Primary ICD-10 Code: \_\_\_\_\_ Secondary ICD-10 Code: \_\_\_\_\_

**Ship to:**  
 Name \_\_\_\_\_ Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_ Phone \_\_\_\_\_

**Prescriber Signature** (Sign either line A or B below.) (Physician attests this is his/her legal signature. **NO STAMPS**)

**A. DISPENSE AS WRITTEN\***
**DATE**
**B. PRODUCT SUBSTITUTION PERMITTED**
**DATE**

\*Certain states require "brand medically necessary" or other language to be handwritten by the prescriber if he/she has made this determination in his/her independent clinical judgment.

**Notes:** The prescriber should comply with state-specific prescription requirements. Noncompliance could result in outreach to the prescriber. All Access Pathways terms and conditions apply.

**Please see Important Safety Information, including Boxed Warning for Risk of Permanent Vision Loss, on page 4. For more information, please see full Prescribing Information and Medication Guide or go to [VIGADRONE.com/PI](http://VIGADRONE.com/PI)**

**Please submit completed pages 2 & 3 and accompanying information by fax, or mail to 24 Summit Park Drive, Suite 101, Pittsburgh, PA 15275**

## WHAT IS VIGADRONE<sup>®</sup>?

VIGADRONE<sup>®</sup> (vigabatrin) powder for Oral Solution is a prescription medicine used for the treatment of:

- **Infantile Spasms (IS)** in babies 1 month to 2 years of age, if you and your healthcare provider decide the possible benefits of taking VIGADRONE are more important than the possible risk of vision loss.
- **Refractory Complex Partial Seizures (CPS)** used along with other treatments to treat adults and children 2 years and older if:
  - o The CPS does not respond well enough to several other treatments, and
  - o You and your healthcare provider decide the possible benefit of taking VIGADRONE is more important than the risk of vision loss.

VIGADRONE should not be the first medicine used to treat CPS.

## WHAT IMPORTANT SAFETY INFORMATION SHOULD I KNOW ABOUT VIGADRONE?

### **WARNING: PERMANENT VISION LOSS**

**See Medication Guide and full Prescribing Information for complete information.**

#### **All people who take VIGADRONE:**

- **You are at risk for permanent vision loss with any amount of vigabatrin.**
- **Your risk of vision loss may be higher the more vigabatrin you take daily and the longer you take it.**
- **It is not possible for your healthcare provider to know when vision loss will happen. It could happen soon after starting VIGADRONE or any time during treatment. It may even happen after treatment has stopped.**

- **Because VIGADRONE might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Your healthcare provider will explain the details of this Program to you.**
- **VIGADRONE can damage the vision of anyone who takes it.** People who take VIGADRONE do not lose all of their vision, but some people can have severe loss, particularly to their ability to see to the side when looking straight ahead (peripheral vision). With **severe vision loss**, you may only be able to see things straight in front of you (sometimes called "tunnel vision"). You may also have **blurry vision**. If this happens, it will not get better.
- **Tell your healthcare provider right away if you (or your child):** might not be seeing as well as before starting VIGADRONE; start to trip, bump into things, or are more clumsy than usual; are surprised by people or things coming in front of you that seem to come out of nowhere; or if your baby is acting differently than normal. **These changes can mean that vision damage has occurred.**
- **Regular vision testing is recommended.** It is recommended that your healthcare provider test your (or your child's) vision before or within 4 weeks after starting VIGADRONE, and at least every 3 months during treatment until VIGADRONE is stopped. It is also recommended that vision be tested about 3 to 6 months after VIGADRONE is stopped. It is difficult to test vision in babies, but to the extent possible, all babies should have their vision tested. Your healthcare provider will determine if testing can be done. **Regular vision testing is important because damage can happen before any changes are noticed.**

- **Vision tests cannot prevent the vision damage** that can happen with VIGADRONE, but they do allow VIGADRONE to be stopped if vision has gotten worse, which usually will lessen further damage. Even these regular vision tests may not show vision damage before it is serious and permanent. **Parents, caregivers, and healthcare providers may not recognize the symptoms, or find vision loss in babies**, until it is severe.
- **If you do not have these vision tests regularly, your healthcare provider may stop prescribing VIGADRONE for you (or your child). Some people are not able to complete vision testing. If vision testing cannot be done, your healthcare provider may continue prescribing VIGADRONE, but will not be able to watch for any vision loss.**
- **Magnetic resonance imaging (MRI) changes in babies with IS.** Brain pictures taken by MRI show changes in some babies after they are given VIGADRONE. It is not known if these changes are harmful.
- **Risk of suicidal thoughts or actions.** Like other antiepileptic drugs, VIGADRONE may cause suicidal thoughts and actions in some people (about 1 in 500 people). Call a healthcare provider right away if you (or your child) have any symptoms, especially sudden changes in mood, behaviors, thoughts or feelings, and especially if they are new, worse, or worry you.
- **Do not stop VIGADRONE without first talking to a healthcare provider.** Stopping VIGADRONE suddenly can cause seizures that will not stop.

**VIGADRONE can cause serious side effects** such as low red blood cell counts (anemia), sleepiness and tiredness, nerve problems, weight gain, and swelling. Because VIGADRONE causes sleepiness and tiredness, do not drive, operate machinery, or perform any hazardous task, unless it is decided that these things can be done safely. VIGADRONE may make certain types of seizures worse. **Tell your healthcare provider right away if seizures get worse.**

**Before starting VIGADRONE, tell your doctor about all of your (or your child's) medical conditions** including depression, mood problems, suicidal thoughts or behavior, any allergic reaction to VIGADRONE, vision problems, kidney problems, low red blood cell counts (anemia), and any nervous or mental illnesses. Tell your doctor about all the medicines you (or your child) take.

**If you are breastfeeding or plan to breastfeed, VIGADRONE can pass into breast milk and may harm your baby.**

**If you are pregnant or plan to become pregnant,** it is not known if VIGADRONE will harm your unborn baby. You and your healthcare provider will have to decide if you should take VIGADRONE while you are pregnant.

**The most common side effects of VIGADRONE in adults include:** blurred vision, sleepiness, dizziness, problems walking or feeling uncoordinated, shaking (tremor) and tiredness.

**The most common side effect of VIGADRONE in children 3 to 16 years of age** is weight gain. Also expect side effects like those seen in adults.

**The most common side effects of VIGADRONE in babies include:** sleepiness (sleepy babies may have a harder time suckling and feeding or may be irritable), swelling in the bronchial tubes (bronchitis), ear infection and irritability.

**Tell your healthcare provider if you or your child have any side effect that bothers you or that does not go away.**

**This is the most important information to know about VIGADRONE, but not all of the possible side effects of VIGADRONE.** For more information, ask your healthcare provider or pharmacist, or please see VIGADRONE Medication Guide, full Prescribing Information including Boxed Warning for risk of permanent vision loss, and Instructions for Use. You can also visit [vigadrone.com](http://vigadrone.com), [upsher-smith.com](http://upsher-smith.com) or call 1-888-650-3789.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-332-1088.